Comparative Pharmacology
Head-to-head clinical analysis: DURYSTA versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURYSTA versus TRAVOPROST.
DURYSTA vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaglandin analog; selective FP receptor agonist that increases uveoscleral outflow of aqueous humor.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
One intracameral implant (10 mcg) administered in the study eye by a qualified ophthalmologist. A second administration may be performed if necessary, at least 3 months after the initial implant.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Not applicable due to local ocular administration with minimal systemic exposure; bimatoprost systemic half-life is approximately 45 minutes after intravenous administration.
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Minimal systemic absorption; no data on specific routes of elimination; expected to be primarily excreted via renal and biliary routes in small amounts.
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."